Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Definium Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the underwriters named therein valued at approximately $93.8 million (effective 2024-03-07).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the underwriters named therein
- Value
- approximately $93.8 million
- Effective
- 2024-03-07
Exact text from the filing
On March 7, 2024, Mind Medicine (MindMed) Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the underwriters named therein (the “Underwriters”), in connection with the issuance and sale by the Company in an underwritten offering (the “Offering”) of 16,666,667 common shares
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Definium Therapeutics, Inc. entered into Purchase Agreement with certain investors valued at approximately $70.3 million (effective 2024-03-07).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors
- Value
- approximately $70.3 million
- Effective
- 2024-03-07
Exact text from the filing
Also on March 7, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Investors agreed to purchase, and the Company agreed to sell 12,500,000 common shares (the “Private Placement Shares”), at a price of $6.00 per Private Placement Share, in a private placement transaction (the “Private Placement”).
View on SEC.gov